About
Miguel Forte is Chief Executive Officer of Kiji Therapeutics and serves as an ARM Board Member. He holds an MD and PhD and brings over 30 years of experience across clinical, academic, regulatory, and pharmaceutical industry settings, with expertise in research and development, manufacturing, regulatory affairs, medical affairs, and general management. He previously served as President of the International Society for Cell & Gene Therapy.
Experience
- Kiji TherapeuticsChief Executive Officercurrent2023 — presentFrance
- ISCT, International Society for Cell & Gene TherapyImmediate Past Presidentcurrent2026 — presentGlobal
- ISCT, International Society for Cell & Gene TherapyVice-Chair Industry - Committee on the Ethics of Cell and Gene Therapy (ECGT)current2019 — presentGlobal
- ISCT, International Society for Cell & Gene TherapyPresident2024 — 2026
- ISCT, International Society for Cell & Gene TherapyBoard Member2018 — 2020Global
- ISCT, International Society for Cell & Gene TherapyChief Commercialization Officer2016 — 2020Global
- ISCT, International Society for Cell & Gene TherapyChair of Commercialization Committee2014 — 2020Global
- ISCT, International Society for Cell & Gene TherapyVice-President Elect European Regional Committee2012 — 2014Europe
- Alliance for Regenerative MedicineExecutive Committee Membercurrent2020 — present
- Alliance for Regenerative MedicineBoard Membercurrent2019 — presentGlobal
- Alliance for Regenerative MedicineMember and Chair of European Advisory Board/Committeecurrent2019 — present
- Alliance for Regenerative MedicineChair of Nomination Committee2019 — 2022
- Blue Cell TherapeuticsNon Executive Directorcurrent2025 — present
- Akatsuki TherapeuticsExecutive Chairmancurrent2025 — present
- Swarm OncologyNon Executive Directorcurrent2024 — presentLondon
- StemBond TechnologiesNon Executive Directorcurrent2023 — present
- StemBond TechnologiesExecutive Chair of Board of Directors2023 — 2025Cambridge, England, United Kingdom
- Made ScientificMember of the Board of Advisorscurrent2025 — present
- mC4TxFounder and Managing Directorcurrent2017 — presentBrussels Area, Belgium
- Faculdade de Farmácia da Universidade de LisboaInvited Associate Professorcurrent2015 — presentLisbon
- AdBio partnersEntrepreneur In Residence2022 — 2023Paris, Île-de-France, France
- essenscia waterlooBoard Member2021 — 2022Brussels Metropolitan Area
- BONE THERAPEUTICS S.A.Chief Executive Officer2020 — 2022Brussels Area, Belgium
- Zelluna ImmunotherapyChief Executive Officer2017 — 2019Oslo Area, Norway
- BONE THERAPEUTICS S.A.Chief Medical Officer2017Belgium
- Universidade de AveiroInvited Associate Professor2010 — 2017Aveiro
- TxCellEVP and Chief Operating Officer2015 — 2016Sophia-Antipolis
- TxCellSVP Clinical and Regulatory Affairs and Chief Medical Officer2010 — 2015Sophia-Antipolis
- UCBVP Global Medical Affairs Inflammation2006 — 2010
- Nabi BiopharmaceuticalsVP Clinical, Regulatory and Medical Affairs Europe2004 — 2006
- Faculdade de Medicina da Universidade de LisboaAuxiliary Professor of Infections Diseases1992 — 2005Hospital Santa Maria - Lisboa, Portugal
- Faculdade de Medicina da Universidade de LisboaConsultant specialist in Infectious Diseases1992 — 1995Hospital Santa Maria - Lisboa, Portugal
- Bristol-Myers SquibbVP International Medical Organization, Europe2002 — 2003
- Bristol-Myers SquibbExecutive Director, Infectious Diseases, Immunology and Dermatology2000 — 2002
- Bristol-Myers SquibbMedical Director, Portugal1998 — 2000
- EMEACHMP Member, Portugal1997 — 1998
- INFARMEDVice-Chairman New Drugs Committee1996 — 1998
- Abbott LaboratoriesMedical Director, Portugal1995 — 1996
- GSKMedical Director1995Lisbon, Portugal
- University of BirminghamClinical Registrar and Research Fellow1988 — 1992
Skills & more
Infectious Diseases33Biopharmaceuticals25Regulatory Affairs29Clinical Development97Immunology59Translational Medicine5Clinical Trials32VaccinesMedical Affairs46Drug Development59Rheumatology2Dermatology4
+12 more
PharmaceuticsBiotechnologyClinical ResearchMarket AccessOncologyHealth EconomicsInflammationMedicinePharmaceutical IndustryCROMedical WritingPharmacologyLanguages English · French · Italian · Portuguese · Spanish
From Miguel's professional profile.
Colleagues at Delin Ventures
Alan Barge
Venture Partner at Delin Ventures
Carol Lynch
Advisor at Delin Ventures
Caroline Haegeman
Associate at Delin Ventures
Christopher Spray
Advisor at Delin Ventures
Colin Sims
Partner at Delin Ventures
Igor Linshits
Founder at Delin Ventures
İskender Dirik
Partner at Delin Ventures
Jakub Czarnecki
Financial Controller at Delin Ventures
Frequently asked questions
- Who is Miguel Forte?
- Miguel Forte is Chief Executive Officer of Kiji Therapeutics and serves as an ARM Board Member. He holds an MD and PhD and brings over 30 years of experience across clinical, academic, regulatory, and pharmaceutical industry settings, with expertise in research and development, manufacturing, regulatory affairs, medical affairs, and general management. He previously served as President of the International Society for Cell & Gene Therapy.
- Where does Miguel Forte work?
- Miguel Forte is Advisor at Delin Ventures.
- Where did Miguel Forte go to school?
- Miguel Forte studied at University of Lisbon (MD, Medicine); University of Birmingham (PhD, Medicine; Immunology; Infectious Diseases); London School of Hygiene and Tropical Medicine, U. of London (DTM&H, Tropical Medicine).
Same school
Also attended University of Lisbon11
Juan LealProduct at Draper B1Iva KubickovaDirector of Community at The 51 VenturesDuarte CaldasInvestments Principal at 3Comma CapitalPaulo MonizExpert Advisory Board — Director of Information Security and IT Risk at EDP at 33NDaniel AmaralBusiness Angel at REDangelsPaulo BandeiraBusiness Angel at REDangels
+ 5 more
Also attended University of Birmingham91
Hal TilyVenture Partner at Rackhouse Venture Management LpStephen ChambersGeneral Partner at SOSVAlexa TanAssociate, ESG & Impact at Openspace VenturesSikander ChahalPrincipal at TRANSCENDSunir KapoorNon-Executive Chairman at Kibo VenturesChloe LeggeInvestor at Extantia Capital
.png)
+ 85 more
Also attended London School of Hygiene and Tropical Medicine, U. of London7
Craig RitchieAlzheimer's Moonshot Impact Board at StartUp HealthLiz GrubinInvestment Principal at Mulago FoundationKemi TesfazghiGates Foundation at i3 — Investing in Innovation AfricaMonique SmithInvestor at Rock Health CapitalRobert W. YehInvestor at Broadview VenturesFaheem AhmedPartner at Anchorless Bangladesh
+ 1 more
Also attended Stockholm School of Economics215
Jeppe RindomCo-founder & CEO of PleoVictor JacobssonCo-founder of Klarna; investorJosefin LandgårdCo-founder & CEO of MANTLE; co-founder of KryMattias LjungmanInvestor at Moonfire VenturesPär-Jörgen PärsonPartner at NorthzoneJessica SchultzPartner at Northzone
+ 209 more
